CIRIUM
6.1.2022 09:21:06 CET | Business Wire | Press release
Aviation analytics firm Cirium, reveals that December was the busiest month in 2021 for flights globally, totaling 2.43 million, however the total number of flights canceled globally between December 24, 2021, and January 3, 2022, was 59,240, some 2.4%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105006010/en/
The number of cancelations over this period is the most cancelations in December for the past decade, six times more than the cancelations in 2019 and two and half times more than 2020. A total of 20,500 flights were canceled in the first three days of the new year.
The big four US airlines, including American Airlines, Delta Air Lines, Southwest Airlines and United Airlines, canceled nearly 7,040 flights over this period.
The cancelations being driven by the surging cases of the Omicron variant of COVID-19 and other operational challenges (including winter weather). Airlines rapidly canceled flights due to staff shortages across crew and ground operations.
Pre-Omicron, global flights flown increased 1.5% week-over-week (December 11-17, 2021). However, global flights are now down 5% compared to the week prior, following the impact of Omicron.
There are large variances between the regions, with the US, Europe and North Atlantic down 9-10%, China up 6%, while Asia-Pacific and Middle East are flat.
“Flight disruptions affect airlines and airports differently – it depends on the availability and flexibility of equipment and resources in place to react quickly. Those that plan more conservatively will minimize their operational disruptions. Cirium monitors the level of disruption by measuring completion factor of flights and their on-time performance,” said Jeremy Bowen CEO at Cirium.
“Cirium’s recent On-Time Performance Review shows how some airlines have focused on their operations to reduce the impact on passengers. For example, Delta Air Lines completed 99.8% of their flights from June to December 2021 and All Nippon Airways, the winner of the Global airline category in Cirium’s Review had a completion factor of 99.2%.”
Consideration is given to the carriers with high volumes of flights. For example, American Airlines flew the most flights in 2021 – around 1,850,050 – and still, its flights arrived 80.47% on time. The carrier did have trouble reinstating flight volumes after more than a year of deeply depressed demand yet completed 97.5% of its flights.
Hartsfield-Jackson Atlanta International Airport (ATL), the major hub for Delta Air Lines, was the busiest airport based on departing flights with 336,890 this year. Despite handling the most flights, it ranked 15th in on-time performance of the Top 20 Global airports.
Amsterdam Airport (AMS) was the busiest airport for international flights in 2021, with a total of 123,070 departing flights, however, it didn’t make the Top 20 airport rankings for on-time performance. Airports have experienced many variables this year in deploying comprehensive pandemic protocols, optimizing the reconciliation and collection of fees and services, and optimizing staffing.
Cirium’s On-Time Performance Review is the industry standard for airlines and airports operational performance. Cirium resumed reporting in June 2021, as flight volumes returned, with regular monthly updates that help gauge the industry’s performance in getting passengers from point A to point B, on time. Cirium’s on-time performance analysis is based on flight data from over 600 sources of real-time flight information.
Click here to download the complimentary On-Time Performance Review 2021.
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insights, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105006010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
